Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin in the Treatment of Benign Prostatic Hyperplasia (BPH) Complicated With Lower Urinary Tract Symptoms (LUTS)
NCT05551221Phase 4Completed
- Sponsor
- Guiyang Xintian Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of silodosin in benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) (2 arms), sponsored by Guiyang Xintian Pharmaceutical Co., Ltd. Primary endpoint: International Prostate Symptom Score at 12 weeks. Started Sep 2022; status: completed.
02
Drugs
silodosin
03
Conditions
benign prostatic hyperplasia (BPH)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT05551221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551221.